Reprieve Cardiovascular
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
459 Fortune Blvd, Milford, Massachusetts...Phone Number
(617) 848-0400Website
www.reprievecardio.comRevenue
$9.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Reprieve Cardiovascular
Reprieve Cardiovascular specializes in intelligent decongestion management solutions for patients with Acute Decompensated Heart Failure. Their flagship product, the Reprieve System, utilizes real-time patient data to enhance diuretic management, aiming to improve patient outcomes and reduce hospitalizations. The company targets healthcare providers and care teams, offering them greater visibility and control over fluid management therapies. Currently, the Reprieve System is in development and available for investigational use in the U.S.Explore more
Reprieve Cardiovascular Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Reprieve Cardiovascular your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Reprieve Cardiovascular is spiking on competitors!
Check if Reprieve Cardiovascular has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Reprieve Cardiovascular has new funding data
Click to see if Reprieve Cardiovascular had a recent Job posting/layoffs
Earning: See what the market has to say on Reprieve Cardiovascular recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Reprieve Cardiovascular
Reprieve Cardiovascular, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Reprieve Cardiovascular launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Reprieve Cardiovascular as Masked Content
Find 3 more new buyers
Compare Similar Companies to Reprieve Cardiovascular
Compare insights from companies similar to Reprieve Cardiovascular, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
-
2007
JB
Jeannette BakkenNetwork Administrator & Clinical Database Programmer & Contractor
Company Profile Activity
Activity Insights
Reprieve Cardiovascular is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Reprieve Cardiovascular is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Reprieve Cardiovascular.
Reprieve Cardiovascular financials insights
Gather financial insights about Reprieve Cardiovascular, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$42M
2025
Series B
$61M
Reprieve Cardiovascular Tech Stack
A closer look at the technologies used by Reprieve Cardiovascular
Reprieve Cardiovascular News & Media
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results from its FASTR randomized pilot study, evaluating the Reprieve System for patients with ADHF compared to optimal diuretic therapy (ODT). The trial met both primary efficacy and safety endpoints. The results were presented by James Udelson, M.D., Principal Investigator of the FASTR trial and Chief of CFirst-In-Human Study Demonstrates the Potential of the Reprieve System in Patients with Acute Decompensated Heart Failure
MILFORD, Mass. & FRANKFURT, Germany--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the first-in-human results of the Reprieve System at the CSI Focus D-HF (Device therapies in heart failure) conference in Frankfurt, Germany. Results of the study demonstrated the potential of the Reprieve System to safely accelerate and maximize decongestion while reducing the likelihood of kidnReprieve Cardiovascular Completes Enrollment in Randomized Pilot Trial Evaluating First-of-its-Kind Personalized Fluid Management System for Acute Decompensated Heart Failure
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced the completion of enrollment in the "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)" trial. The FASTR trial aims to compare the effectiveness of decongestive therapy administered by the Reprieve System witReprieve Cardiovascular Raises $42M in Series A Financing
Reprieve Cardiovascular, a Milford, MA-based development stage company focused on an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, raised $42M in Series A funding. The round was led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures. The company intends to […] The post Reprieve Cardiovascular Raises $42M in Series A Financing appeared first on FinSMEs.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Reprieve Cardiovascular
Sign Up For FreeTo access detailed company insights
Reprieve Cardiovascular specializes in intelligent decongestion management solutions for patients with Acute Decompensated Heart Failure. Their flagship product, the Reprieve System, utilizes real-time patient data to enhance diuretic management, aiming to improve patient outcomes and reduce hospitalizations. The company targets healthcare provider... Read More
